Conditions · Pediatrics and neonatology
Neonatal abstinence syndrome !
Withdrawal signs in a newborn exposed to opioids or other drugs in the womb. The baby is irritable, feeds poorly and may need treatment.
Updated 2026-11-01
Structures involved
Tap one to see what it is and open it in 3D.
Why it happens
What it is
A drug-withdrawal syndrome in newborns exposed in utero to substances, mainly opioids, causing central nervous system, autonomic and gastrointestinal signs in the first days of life. When it refers specifically to opioids it is also called neonatal opioid withdrawal syndrome (NOWS).
Who gets it
Rose sharply in North America with the opioid epidemic. In Colombia and Latin America, maternal opioid use is less frequent, but exposure to heroin, prescribed opioids, benzodiazepines, alcohol and other substances is seen, especially in large cities; it is likely under-recognised.
Causes
- Prenatal exposure to opioids: heroin, methadone, buprenorphine or prescribed analgesic opioids
- Other substances that cause similar signs: benzodiazepines, barbiturates, some antidepressants, alcohol and nicotine
- Abrupt interruption of the drug supply at birth
Risk factors
- Maternal opioid use disorder or chronic opioid therapy in pregnancy
- Use of several substances (polysubstance exposure), including tobacco
- Term birth (preterm babies often show milder signs)
- Limited prenatal care
Pathophysiology
Opioids cross the placenta and the fetus adapts to them. After birth the supply stops, and the loss of opioid receptor inhibition leads to excess release of noradrenaline and other neurotransmitters. This produces central nervous system hyperexcitability, autonomic overactivity and gastrointestinal dysfunction. Timing depends on the drug half-life: short-acting opioids within 1 to 2 days, methadone or buprenorphine often later.
Symptoms and signs
- High-pitched, excessive crying and irritability
- Tremors, increased muscle tone, hyperactive reflexes and poor sleep
- Poor feeding, uncoordinated sucking, vomiting and diarrhoea
- Sweating, fever, sneezing, nasal stuffiness and yawning
- Tachypnoea, mottled skin and excoriation from constant movement
- Poor weight gain
Diagnosis
- Clinical
- Maternal history of substance use plus compatible signs. Severity is followed with structured tools (for example the Finnegan score or the «Eat, Sleep, Console» approach).
- Tests
- Toxicology of newborn urine, meconium or umbilical cord tissue to confirm exposure. Glucose, electrolytes, calcium and, when indicated, blood count and cultures to rule out other causes.
- Imaging
- Not needed for diagnosis; cranial ultrasound only if another neurological problem is suspected.
Differential diagnosis
- Neonatal sepsis or meningitis
- Hypoglycaemia, hypocalcaemia or hypomagnesaemia
- Hypoxic-ischaemic encephalopathy or intracranial haemorrhage
- Neonatal hyperthyroidism
- Fetal alcohol spectrum effects
Goal of treatment
Help the baby eat, sleep and be consoled, support weight gain and parent-infant bonding, and use medication only when non-drug care is not enough.
Treatment
- Follow-up
- Regular assessment with a standard scoring tool; monitoring of weight, intake, hydration and vital signs.
- Conservative
- Non-drug care first: rooming-in with the parents, skin-to-skin contact, swaddling, a dim quiet room, frequent small feeds and breastfeeding when the mother is in a stable treatment programme.
- Medical
- Opioid replacement (morphine, methadone or buprenorphine) for moderate to severe withdrawal, with slow tapering; phenobarbital or clonidine as add-ons in some cases.
- Follow-up
- Discharge planning with social work, maternal addiction treatment and follow-up of growth and development.
Complications
- Seizures
- Dehydration, poor weight gain and failure to thrive
- Skin breakdown
- Long hospital stay and disrupted bonding
- Higher risk of developmental and behavioural problems (also linked to the home environment)
Prognosis
The acute syndrome resolves over days to weeks. Long-term outcome depends on the substances involved, prematurity and, above all, the caregiving environment and family support.
Prevention
- Screening for substance use in prenatal care
- Treatment of maternal opioid use disorder with supervised opioid agonist therapy instead of abrupt withdrawal in pregnancy
- Careful prescribing of opioids during pregnancy
Test yourself
Think of the answer, then tap the question to see it.
Which drug class is the main cause of neonatal abstinence syndrome?
Opioids taken during pregnancy, whether illicit, prescribed or as agonist treatment.
What is the first-line management of neonatal abstinence syndrome?
Non-drug care: rooming-in, skin-to-skin, swaddling, a quiet setting, frequent feeds and breastfeeding when appropriate.
Which drug class is used when withdrawal signs are severe?
An opioid (morphine, methadone or buprenorphine) given and slowly tapered; phenobarbital or clonidine may be added.
Why may withdrawal from methadone start later than withdrawal from heroin?
Methadone has a longer half-life, so signs often appear after the first two to three days.
Which conditions must be ruled out in a jittery, irritable newborn?
Hypoglycaemia, hypocalcaemia, sepsis or meningitis, and brain injury such as hypoxic-ischaemic encephalopathy.
Related conditions
- Opioid use disorder, overdose and withdrawal
- Neonatal hypoglycaemia (including infant of a diabetic mother)
- Neonatal sepsis
- Fetal alcohol spectrum disorder
- Sudden infant death syndrome (SIDS)
- Failure to thrive (faltering growth)
Educational information, not medical advice. For any symptom, see a health professional.
Sources: Neonatal abstinence syndrome (MedlinePlus (U.S. National Library of Medicine), 2024).
Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake
Representative model, for educational purposes only.
